ArticleInternational journal of molecular sciences2025
Diosmin or Hesperidin? Comparison of Antioxidative Action of Two Venoactive Flavonoids in Type 1 Diabetic Rats.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Diabetes mellitus and chronic venous disease (CVD) are multifactorial, long-lasting diseases. Although usually considered separately, they often coexist, and individuals with diabetes are more prone to CVD development. Despite different etiology, CVD and diabetic vascular complications share several pathomechanisms, and oxidative stress is one of them. In this study the antioxidative potential of two venoactive flavonoids-diosmin and hesperidin-in the course of type 1 diabetes was compared for the first time. Type 1 diabetic rats were treated with diosmin or hesperidin, each at two doses, 50 and 100 mg/kg, for four weeks. In order to evaluate the antioxidative potential of tested compounds, the antioxidative enzyme activity (superoxide dismutase, catalase and glutathione peroxidase), thiols homeostasis, oxidative status markers (total antioxidative response-TAR, total oxidative status and oxidative stress index-OSI), and oxidative damage markers (advanced oxidation protein products and malondialdehyde) in the serum were measured. Diabetes caused disturbance in the serological redox homeostasis, especially by decreasing enzyme activity and TAR while increasing levels of oxidative damage markers and OSI, increasing advanced glycation end products (AGEs) levels, as well as altering carbohydrate and lipid metabolism. Flavonoids improved the majority of lipid metabolism markers and reduced AGEs with no effect on glycemia. In the context of oxidative stress, their effect was moderate and dose-dependent, and better potency of hesperidin over diosmin was noted, both in individual and multivariate analyses of the parameters. The collective analysis of all parameters led to the conclusion that both diosmin and hesperidin can be considered complementary agents averting negative impact of diabetes due to their multi-faceted actions, including antioxidative properties.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.